INCY Key Statistics, Chart & Performance
The current stock price of INCY is 100.07 USD. In the past month the price increased by 1.32%. In the past year, price increased by 34.94%.
INCY Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to INCY. When comparing the yearly performance of all stocks, INCY is one of the better performing stocks in the market, outperforming 82.68% of all stocks.
INCY Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to INCY. INCY gets an excellent profitability rating and is at the same time showing great financial health properties.
INCY Financial Highlights
Over the last trailing twelve months INCY reported a non-GAAP Earnings per Share(EPS) of 6.42. The EPS increased by 575.79% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 24.69% | ||
| ROA | 18.78% | ||
| ROE | 25.55% | ||
| Debt/Equity | 0.01 |
INCY Forecast & Estimates
32 analysts have analysed INCY and the average price target is 104.13 USD. This implies a price increase of 4.06% is expected in the next year compared to the current price of 100.07.
For the next year, analysts expect an EPS growth of 428.83% and a revenue growth 18.3% for INCY
INCY Ownership
INCY Latest News, Press Relases and Analysis
About INCY
Company Profile
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. The company is headquartered in Wilmington, Delaware and currently employs 2,617 full-time employees. The firm operates in two therapeutic areas. One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of six products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), NIKTIMVO (axatilimab-csfr), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. The firm's pipeline also includes two first-in-class small molecule antagonist of Mas-related G protein-coupled receptor (MRGPRX2) and INCB000547, an oral MRGPRX4 antagonist.
Company Info
INCYTE CORP
1801 Augustine Cut-Off
Wilmington DELAWARE 19803 US
CEO: Herve Hoppenot
Employees: 2617
Phone: 13024986700
INCYTE CORP / INCY FAQ
What does INCY do?
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. The company is headquartered in Wilmington, Delaware and currently employs 2,617 full-time employees. The firm operates in two therapeutic areas. One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of six products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), NIKTIMVO (axatilimab-csfr), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. The firm's pipeline also includes two first-in-class small molecule antagonist of Mas-related G protein-coupled receptor (MRGPRX2) and INCB000547, an oral MRGPRX4 antagonist.
What is the stock price of INCYTE CORP today?
The current stock price of INCY is 100.07 USD. The price decreased by -1% in the last trading session.
Does INCYTE CORP pay dividends?
INCY does not pay a dividend.
What is the ChartMill technical and fundamental rating of INCY stock?
INCY has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
Can you provide the PE ratio for INCY stock?
The PE ratio for INCYTE CORP (INCY) is 15.59. This is based on the reported non-GAAP earnings per share of 6.42 and the current share price of 100.07 USD.
Would investing in INCYTE CORP be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on INCY.